Remove 2028 Remove Healthcare Remove Safety
article thumbnail

The EU AI Act: will regulation drive life science innovation away from Europe?

European Pharmaceutical Review

This dual-layer certification process can create significant delays, as each framework involves extensive assessments for safety and performance under separate requirements specific to medical device and AI-specific criteria. Alex has a BSc in Human Genetics. References 1.

Medical 105
article thumbnail

What Is Pharma Marketing in 2025?

PM360

Globalization and health equity: Healthcare is global, and patients are diverse. Globalization: Healthcare for All Healthcare systems worldwide face challenges including rising chronic diseases, aging populations, workforce shortages, and sustainability concerns. But the extent to which brands still have U.S.-insured-only

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Non-Invasive Healthcare Products Buy and Sell

Contrarian Sales Techniques

Non-invasive healthcare products refer to medical devices or technologies that do not require puncturing the skin or entering the body in any way to diagnose, treat, or monitor a health condition. The market for non-invasive healthcare products is expected to grow significantly in the coming years.

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

What really matters are the orthopedic medical device trends that are already shaping the healthcare industry. Advancements in medical technology will always be a favorite topic of discussion when analyzing the healthcare sector. million by 2028. Healthcare executives are also looking into AR spinal surgical systems.

Medical 98
article thumbnail

Biosimilars: The Future of Affordable Biologic Therapies

Pharmaceutical Representative Training

Biosimilars: The Future of Affordable Biologic Therapies Biologics are some of the most expensive forms of therapy in modern healthcare. However, there are products that can help bridge the affordability gap created by these biologics, while also providing similar efficacy and safety for patient treatment.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

What really matters are the orthopedic medical device trends that are already shaping the healthcare industry. Advancements in medical technology will always be a favorite topic of discussion when analyzing the healthcare sector. million by 2028. Healthcare executives are also looking into AR spinal surgical systems.

Medical 52